AFM Portaal en AFM-website niet bereikbaar komend weekend
Vanaf vrijdag 4 oktober 21.00 uur tot zondag 6 oktober 21.00 uur is het AFM Portaal niet bereikbaar. Vanaf zaterdag 5 oktober 06.00 uur tot zondag 6 oktober 21.00 uur is de AFM-website niet bereikbaar.
OctoPlus N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
15 okt 2008 - 20:16
Statutaire naam
OctoPlus N.V.
Titel
OCTOPLUS ANNOUNCES 2008 FIRST HALF-YEAR RESULTS AND PUBLICATION OF 2007 ANNUAL REPORT
Bericht
Leiden, the Netherlands, 16 October 2008 – OctoPlus N.V. (“OctoPlus” or “the Company”) (Euronext: OCTO), the drug delivery company, announces today its results for the six-month period ended 30 June 2008. The Company also announces the publication of its Annual Report 2007.
Financial and product highlights
- 30% increase in external revenues for the six-month period from € 2,874k in 2007 to € 3,738k in 2008
- Exclusive license and product acquisition agreement signed with Biolex Therapeutics for OctoPlus’ lead product Locteron®, with upfront and milestone payments up to US$ 149 million and royalties on future Locteron sales, as well as a product supply and manufacturing agreement signed with Biolex for the further development and manufacturing of Locteron
- Additional financing secured up to € 4.0 million through convertible bridge loans
- Significant product progress: Locteron Phase IIa PLUS study ongoing in the United States and clinical proof of concept achieved in OP-145 Phase II ear infection study
- Nomination of two additional members to the Executive Board, including a new CEO with international experience in leading a public life sciences company
Datum laatste update: 06 oktober 2024